| Date | Filer | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Jun 09, 2022 |
Director
Trans History: 2
|
Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 164,422 | -- | 164,422 |
| Jul 07, 2022 |
Director
Trans History: 18
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 44,470 | $0.51 | 58,364 |
| Jul 07, 2022 |
Director
Trans History: 18
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 44,470 | -- | -- |
| Aug 15, 2022 |
Director
Trans History: 11
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 20,000 | $0.38 | 20,000 |
| Aug 15, 2022 |
Director
Trans History: 11
|
Director | Form 4 | Open market or private sale of non-derivative or derivative security | 20,000 | $3.62 | -- |
| Aug 15, 2022 |
Director
Trans History: 11
|
Director | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 20,000 | -- | 60,923 |
| Feb 15, 2023 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 120,000 | -- | 124,794 |
| Feb 15, 2023 |
Chief Medical Officer
Trans History: 12
|
Chief Medical Officer | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 560,000 | -- | 560,000 |
| Feb 15, 2023 |
Director, President and CEO
Trans History: 29
|
Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 300,000 | -- | 841,615 |
| Feb 15, 2023 |
Director, President and CEO
Trans History: 29
|
Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 1,400,000 | -- | 1,400,000 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.